Hi! Welcome Back and Stay Tune! Here’s how often IBM’s Watson agrees with doctors on the best way to treat cancer - Mukah Pages : Media Marketing Make Easy With 24/7 Auto-Post System. Find Out How It Was Done!

Header Ads

Here’s how often IBM’s Watson agrees with doctors on the best way to treat cancer

IBM Watson Office 27

Hollis Johnson

We’re starting to get a better picture of how artificial intelligence could help doctors better treat cancer. 

And in data presented at the American Society of Clinical Oncology meeting, IBM Watson Health gave a snapshot of how it’s playing out so far. 

The studies looked at concordance rates, or how often Watson for Oncology reached the same course of treatment as the cancer doctors at different cancer centers around the world. At Manipal Comprehensive Cancer Center in India, for 112 cases of lung cancer, there was 96.4% concordance between Watson and the doctors. For 126 cases of colon cancer it was 81% of the time, and for 124 cases of rectal cancer cases were 92.7%. 

The concordance was in line with what IBM expected in those cases: If Watson and the docs agreed all the time, there wouldn’t be much value for adding AI to the picture.

But it was a bit off when it came to Watson evaluating 185 cases of gastric cancer in South Korea. There, the concordance was 49%. Norden said that relates to the guidelines for gastric cancer being different in South Korea than at Memorial Sloan Kettering, the hospital where Watson for Oncology was trained. 

The data presented at ASCO are among the first that IBM Watson Health has presented at a medical conference. And while it sets the stage for what artificial intelligence can do to help doctors treat patients with cancer, many still have lingering questions.

The biggest yet-to-be-answered question: Can using AI to determine cancer treatment actually extend patients’ lives compared to oncologists alone determining their treatments?

Andrew Norden, the deputy chief health officer at IBM Watson Health told Business Insider that the concordance data isn’t “the ultimate endpoint we’re interested in,” though it was the first they could get to relatively quickly.

To get to studies that evaluate overall survival (that is, finding out whether using AI-powered treatment plans can increase patients’ lives compared to traditional treatment plans) will take more time.

Get the latest IBM stock price here.

NOW WATCH: SCOTT GALLOWAY: WeWork is arguably the most overvalued company in the world

Please enable Javascript to watch this video

Read more stories on Business Insider, Malaysian edition of the world’s fastest-growing business and technology news website.



✍ Sumber Pautan : ☕ Business InsiderBusiness Insider

Kredit kepada pemilik laman asal dan sekira berminat untuk meneruskan bacaan sila klik link atau copy paste ke web server : http://ift.tt/2rNmWZS

(✿◠‿◠)✌ Mukah Pages : Pautan Viral Media Sensasi Tanpa Henti. Memuat-naik beraneka jenis artikel menarik setiap detik tanpa henti dari pelbagai sumber. Selamat membaca dan jangan lupa untuk 👍 Like & 💕 Share di media sosial anda!

No comments

Comments are welcome and encouraged on this site. Comments deemed to be spam or solely promotional will be deleted. Including link to relevant content is permitted, but comments should be relevant to the post topic.

Comments including profanity and containing language that could deemed offensive will also deleted. Please respectful toward other contributors. Thank you.